ArticleInternational journal of pharmaceutics: X2025
Liposomal glytrexate formulation: improving antitumour efficacy and minimizing toxicity in breast cancer therapy.
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a critical global health challenge with increasing incidence rates. This study reports the first successful encapsulation of glytrexate (GTX), a novel 6-substituted-pyrrolo [2,3-d] pyrimidine compound, into liposomes. This innovative formulation increases the stability, half-life, and bioavailability of GTX while significantly reducing toxicity. GTX liposomes, with a uniform spherical shape and an average particle size of 121.7 ± 2.9 nm, demonstrated a satisfactory encapsulation efficiency (24.2 ± 0.99 %). Compared to the free drug, GTX liposomes exhibited significantly enhanced inhibitory effects on 4 T1, A549, and MCF-7 cells in vitro. The pharmacokinetic analysis showed prolonged circulation (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.